1. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies
   Josepmaria Argemi et al, 2022, Hepatobiliary Cancers: Translational Advances and Molecular Medicine CrossRef
2. Long-Term Survival of a Lynch Syndrome Patient With Eight Primary Tumors: A Case Report
   Jing Jiang et al, 2022, Frontiers in Oncology CrossRef
3. Discordant microsatellite instability findings in two samples from a patient with biliary cancer that responded to pembrolizumab
   Hiroyuki Matsubayashi et al, 2023, Clinical Journal of Gastroenterology CrossRef
4. Targeted Therapies in Advanced Cholangiocarcinoma
   Michael H. Storandt et al, 2023, Life CrossRef
5. Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
   Giorgio Frega et al, 2023, Cells CrossRef
6. The biliary tree musketeers: cholangiocarcinoma – one name for all, but at least three different diseases with distinct targets
   Lidiane Vieira Marins et al, 2024, Surgical and Experimental Pathology CrossRef
7. Current and emerging immunotherapeutic approaches for biliary tract cancers
   Zhen-Gang Yuan et al, 2022, Hepatobiliary & Pancreatic Diseases International CrossRef
8. Microsatellite instability in patients with hepato-biliary-pancreatic malignancies in clinical practice (KHBO 1903)
   Shoji Kubo et al, 2022, International Journal of Clinical Oncology CrossRef
9. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
   Robin Kate Kelley et al, 2023, The Lancet CrossRef
10. Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: A retrospective analysis from the Finnish National Lynch Syndrome Research Registry
    Kristina Zalevskaja et al, 2023, Frontiers in Oncology CrossRef